Synteract and HCR Complete Merger to Become Global CRO

- Last updated on GMT

Related tags: Clinical trial

Synteract and HCR merge
Synteract and HCR merge
Following its acquisition of HCR, Synteract has become a multinational CRO with a presence in 16 countries.

The completed deal sees CRO (contract research organization) Synteract takeover Munich-based Harrison Clinical Research to become SynteractHCR, creating a combined workforce of over 800 operating in 16 countries.

Speaking in January​ to Outsourcing-Pharma.com, a spokesman said that the acquisition was motivated by global expansion, allowing the company to have a “strong geographical presence in Western and Eastern Europe and an emerging presence in South America.”

Headquartered in San Diego, California, the company will offer its clients clinical support in drug development and managing Phase I-IV clinical trials across multiple therapeutic areas.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars